Ginkgo Bioworks Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$1.6B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ginkgo Bioworks's estimated annual revenue is currently $197.4M per year.(i)
  • Ginkgo Bioworks received $275.0M in venture funding in December 2017.
  • Ginkgo Bioworks's estimated revenue per employee is $224,318
  • Ginkgo Bioworks's total funding is $1.6B.
  • Ginkgo Bioworks's current valuation is $8.6B. (January 2022}

Employee Data

  • Ginkgo Bioworks has 880 Employees.(i)
  • Ginkgo Bioworks grew their employee count by 27% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$356.8M120532%$1.8B$1.5B
#2
$19.6M563-31%$974.1M$562.2M
#3
$3.2M32N/A$20MN/A

The Organism Company Ginkgo Bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. Our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Robotics,Wind Power

$1.6B

Total Funding

880

Number of Employees

$197.4M

Revenue (est)

27%

Employee Growth %

$8.6B

Valuation

Y Combinator

Accelerator

Ginkgo Bioworks News

2021-11-08 - Ginkgo Bioworks Announces Date of Third Quarter 2021 Results Presentation

BOSTON, Nov. 8, 2021 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2021, on Monday, November 15, 202 ...

2021-11-11 - Ginkgo Bioworks Launches Cell Development Kit Service for Standardized, Low-Cost Entry to its Cell Programming Platform

BOSTON, Nov. 11, 2021 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells ...

2021-11-24 - Ginkgo Bioworks Announces Participation in Upcoming Conferences

BOSTON, Nov. 24, 2021 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences: Piper Sandler Annual Healthcare Conference on Tuesday, November 30, 2021 J ...

09/03/2019 - Ginkgo Bioworks Spinoff Raises $27M, Rebrands as ...

Motif, a Ginkgo Bioworks spinoff that exited stealth in February with $90 million in Series A, raised $27.5 million in an extended round of funding ...

09/08/2019 - Motif Unveils New Name and $27.5M to Build Food ...

Motif is based on research from Ginkgo Bioworks, a synthetic biology company that engineers microbes to produce compounds used in a wide ...

09/03/2019 - This New Animal-Free Ingredient Company Just Raised Another $27.5 Million In Funding

Motif Ingredients, the company launched by synthetic biology firm Ginkgo Bioworks, announced today it has raised an additional $27.5 million ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$197.4M88027%$1.6B
#2
$332.6M8806%N/A
#3
N/A90012%N/A
#4
$189.4M9027%N/A
#5
$183.3M903N/AN/A

Ginkgo Bioworks Funding

DateAmountRoundLead InvestorsReference
2015-03-19$9.0MAMultipleArticle
2015-07-24$45.0MBArticle
2016-06-09$100.0MCMultipleArticle
2017-12-15$275.0MDGeneral AtlanticArticle